Alpa Laboratories Limited has informed the Exchange regarding Board meeting held on August 13, 2025.
ALPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Alpa Laboratories Limited, at a meeting held on August 13, 2025, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26), along with the notice for the 37th Annual General Meeting. On a standalone basis, revenue from operations declined about 10.9% year-on-year to ₹1,911.07 lakhs (from ₹2,144.37 lakhs in Q1 FY25), while profit after tax surged roughly 130% to ₹1,177.59 lakhs (from ₹512.45 lakhs). The sharp jump in profit is almost entirely driven by a steep rise in 'other income' to ₹1,195.78 lakhs, which the company notes includes unrealised profit from the mark-to-market gain in fair value of its investments. Core operating metrics such as revenue and cost of materials consumed were weaker compared to the year-ago quarter. Consolidated results were largely in line with standalone, with the subsidiary Norfolk Mercantile Private Limited contributing negligible revenue and a small loss of ₹0.81 lakhs.
Headline profit nearly doubled, but the gain is largely driven by a one-time, non-cash mark-to-market uptick in investment value rather than stronger core pharma operations, and revenue actually shrank year-on-year. Investors should look through the headline PAT growth and watch whether the core Drugs & Chemicals business can stabilise revenue in upcoming quarters before drawing positive conclusions.